Merck's Dolaverin listing is expected to help HIV-infected people cope with dyslipidemia

Merck announced on June 11, which served monolithic compound preparation De Sizhuo ^® (Duo Lami for tablets, Dora Waring 100mg / lamivudine 300mg / tenofovir disoproxil fumarate ester 300mg, DOR / 3TC / TDF), served on a monolithic single-drug agents Peizhuo ^® (Dora ribavirin tablets 100mg) officially launched in China for the treatment of adults with HIV-1 virus infection

95 % of the commonly used drugs of infected people have blood lipid effects

Professor Li Taisheng, director of the Department of Infectious Medicine at the Chinese Academy of Medical Sciences and Peking Union Medical College Hospital , said in an interview with the media that the complications caused by HIV long-term antiviral treatment have attracted more and more attention and have become the most important cause of death and quality of life of infected persons.

Professor Zhang Fujie, director of the Infection Clinic and Research Center of Beijing Ditan Hospital of Capital Medical University, said in an interview that in the process of long-term antiretroviral treatment, whether it is the first-line domestic free antiretroviral treatment plan or the follow-up second-line treatment plan, it contains the right Drugs that have an important effect on blood lipid metabolism

Professor Li Taisheng shared relevant data: the dyslipidemia rate of HIV-infected persons is more than 60%, which is 20% to 30% higher than that of HIV-negative people of the same age group.

Innovative solutions can be considered to deal with dyslipidemia

A recent survey of HIV-infected people in China published by "Physician Daily" found that blood lipids are considered as an important factor or even the primary factor when changing treatment regimens for treated patients (people with medication experience)

"The newly launched dolaverin as a new generation of non-nucleoside reversal enzyme inhibitors solves the two major problems of non-nucleoside in the past and provides more options for patient treatment

In terms of improving the availability of drugs and reducing the financial burden of patients, the two professors also called for more and better drugs to be included in the national free drug list and national medical insurance to provide help for many HIV patients with financial difficulties

references:

1.